Godavari Drugs Ltd (530317) — Board Meeting | 1 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approved amendment to memorandum adding nutraceutical business objective
🔄 What Changed
Added new Main Object No. 4 for nutraceuticals and dietary supplements
🔮 What's Next
Special resolution to be voted on at 38th AGM on 25 September 2026

Godavari Drugs announced board approval to amend its memorandum to add a new business objective for nutraceuticals and dietary supplements, requiring shareholder approval via special resolution at the upcoming 38th AGM on 25 September 2026. The amendment is additive and does not affect existing operations.

📄 View Original Announcement (PDF)

About Godavari Drugs Ltd (530317)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹99.25 Cr P/E: 19.0 ROE: 9.6% ROCE: 8.4%

View full 530317 stock details →

📡 Get AI alerts when 530317 files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track 530317 — Free

📊 More 530317 filings

See all 530317 filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day